Israel Englander Adma Biologics, Inc. Transaction History

Millennium Management LLC

$192 Billion
Q2 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 1,135,756 shares of ADMA stock, worth $19 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,135,756

Previous 2,146,309 47.08%

Holding current value

$19 Million

Previous $42.6 Million 51.43%

% of portfolio

0.01%

Previous 0.02%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$17.6 - $24.51 $17.8 Million - $24.8 Million	-1,010,553 Reduced 47.08%	1,135,756 $20.7 Million
Q1 2025 May 15, 2025	BUY	$15.44 - $20.61 $15.2 Million - $20.3 Million	986,776 Added 85.1%	2,146,309 $42.6 Million
Q4 2024 Feb 14, 2025	BUY	$15.62 - $22.62 $665,458 - $963,679	42,603 Added 3.81%	1,159,533 $19.9 Million
Q3 2024 Nov 14, 2024	BUY	$11.21 - $20.03 $1.98 Million - $3.53 Million	176,275 Added 18.74%	1,116,930 $22.3 Million
Q2 2024 Aug 14, 2024	SELL	$5.98 - $11.18 $4.6 Million - $8.6 Million	-769,366 Reduced 44.99%	940,655 $10.5 Million
Q1 2024 May 15, 2024	SELL	$4.4 - $6.74 $7.66 Million - $11.7 Million	-1,741,846 Reduced 50.46%	1,710,021 $11.3 Million
Q4 2023 Feb 14, 2024	BUY	$3.08 - $4.52 $1.67 Million - $2.45 Million	541,681 Added 18.61%	3,451,867 $15.6 Million
Q2 2023 Aug 14, 2023	SELL	$3.12 - $4.22 $7.69 Million - $10.4 Million	-2,463,315 Reduced 45.84%	2,910,186 $10.7 Million
Q1 2023 May 15, 2023	BUY	$3.01 - $3.87 $230,927 - $296,906	76,720 Added 1.45%	5,373,501 $17.8 Million
Q4 2022 Feb 14, 2023	BUY	$2.47 - $3.88 $8.82 Million - $13.9 Million	3,569,778 Added 206.7%	5,296,781 $20.6 Million
Q3 2022 Nov 14, 2022	SELL	$2.03 - $2.86 $8.45 Million - $11.9 Million	-4,162,968 Reduced 70.68%	1,727,003 $4.2 Million
Q2 2022 Aug 15, 2022	BUY	$1.43 - $2.2 $3.62 Million - $5.57 Million	2,531,272 Added 75.36%	5,889,971 $11.7 Million
Q1 2022 May 16, 2022	BUY	$1.28 - $1.83 $4.08 Million - $5.84 Million	3,189,501 Added 1885.07%	3,358,699 $6.15 Million
Q4 2021 Feb 14, 2022	SELL	$1.09 - $1.66 $449,536 - $684,615	-412,419 Reduced 70.91%	169,198 $239,000
Q3 2021 Nov 15, 2021	SELL	$1.13 - $1.65 $475,186 - $693,856	-420,519 Reduced 41.96%	581,617 $657,000
Q2 2021 Aug 16, 2021	BUY	$1.51 - $2.07 $1.51 Million - $2.07 Million	1,002,136 New	1,002,136 $1.6 Million
Q1 2021 May 17, 2021	SELL	$1.67 - $2.95 $87,280 - $154,178	-52,264 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$1.8 - $2.56 $36,930 - $52,523	20,517 Added 64.63%	52,264 $102,000
Q3 2020 Nov 16, 2020	SELL	$2.04 - $3.74 $593,803 - $1.09 Million	-291,080 Reduced 90.17%	31,747 $76,000
Q2 2020 Aug 14, 2020	BUY	$2.42 - $3.29 $311,514 - $423,505	128,725 Added 66.32%	322,827 $946,000
Q1 2020 May 14, 2020	SELL	$1.5 - $4.59 $107,998 - $330,475	-71,999 Reduced 27.06%	194,102 $559,000
Q4 2019 Feb 14, 2020	SELL	$3.89 - $5.15 $2.32 Million - $3.07 Million	-596,418 Reduced 69.15%	266,101 $1.06 Million
Q3 2019 Nov 14, 2019	BUY	$3.19 - $5.39 $2.37 Million - $4.01 Million	743,506 Added 624.73%	862,519 $3.84 Million
Q2 2019 Aug 15, 2019	BUY	$3.52 - $5.24 $418,925 - $623,628	119,013 New	119,013 $461,000
Q3 2018 Nov 14, 2018	SELL	$4.39 - $6.85 $1.01 Million - $1.57 Million	-229,416 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$4.39 - $5.44 $194,059 - $240,475	-44,205 Reduced 16.16%	229,416 $1.04 Million
Q1 2018 May 15, 2018	BUY	$3.21 - $5.21 $661,542 - $1.07 Million	206,088 Added 305.17%	273,621 $1.26 Million
Q4 2017 Feb 14, 2018	BUY	$2.06 - $3.24 $99,817 - $156,994	48,455 Added 253.98%	67,533 $217,000
Q3 2017 Nov 14, 2017	BUY	$2.76 - $3.71 $52,655 - $70,779	19,078	19,078 $59,000

Others Institutions Holding ADMA

# of Institutions

407

Shares Held

193M

Call Options Held

2.13M

Put Options Held

1.59M

View Full List

About ADMA BIOLOGICS, INC.

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.29B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

More about ADMA

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account